HSBC WAR. CALL 01/25 22UA/ DE000HG1J8A9 /
5/31/2024 9:36:06 PM | Chg.+0.0070 | Bid9:59:31 PM | Ask9:59:31 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.0450EUR | +18.42% | 0.0440 Bid Size: 150,000 |
0.0590 Ask Size: 150,000 |
BIONTECH SE SPON. AD... | 218.4658 - | 1/15/2025 | Call |
GlobeNewswire
5/29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
5/21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
5/17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
4/22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
4/7
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
3/20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
3/20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
3/11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
3/6
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
2/8
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
1/31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
1/22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire
1/9
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
12/21/2023
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire
12/18/2023
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
11/6/2023
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update